Oral Herpes Treatments
Find Oral Herpes Treatments
Brand Name
Vyjuvek
View Brand InformationFDA approval date: May 19, 2023
Form: Kit
What is Vyjuvek?
VYJUVEK is indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation in the collagen type VII alpha 1 chain gene. VYJUVEK is a herpes-simplex virus type 1 vector-based gene therapy indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation in the collagen type VII alpha 1 chain gene.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
Summary: The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.